Literature DB >> 7533451

Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.

S A Kaplan1, E T Goluboff, C A Olsson, P A Deverka, J J Chmiel.   

Abstract

OBJECTIVES: To determine the effect of patient's age, race, Boyarsky score, and urinary flow rate on type of treatment selected for benign prostatic hyperplasia (BPH) and to evaluate maintenance of treatment at 1-year follow-up.
METHODS: Subjects in this prospective study, conducted in a referral center prostate clinic, were 174 consecutive patients, aged 67.6 +/- 10.8 years (mean +/- SD), with previously untreated BPH. Patients underwent structured interviews and uroflowmetry, then completed the Boyarsky Symptom Index. Blinded to these data, one physician described four treatment categories in a nonjudgmental fashion, always using the same order: watchful waiting; finasteride and alpha-blocker; thermal therapy, balloon dilation, and a prostate stent; and transurethral prostate resection. Treatment choice was entirely that of the patient. Independent variables were patient's age, race, symptom score, and uroflow; the dependent variable was treatment choice. At 1 year, the same physician interviewed patients to evaluate maintenance of therapy.
RESULTS: Only symptom score and flow rate were predictive of treatment choice, high scores and low flow being associated with more aggressive treatment choices (P = 0.001). Most patients, regardless of symptom severity, chose interventions less aggressive than surgery and more aggressive than watchful waiting. At 1 year, 85% of patients continued to be maintained on their original treatment.
CONCLUSIONS: Men with mild or moderate BPH prefer interventions of moderate aggressiveness; race and age make little or no difference. If maintenance of treatment indicates patient satisfaction, most patients appear to remain satisfied with therapy they select.

Entities:  

Mesh:

Year:  1995        PMID: 7533451     DOI: 10.1016/S0090-4295(99)80007-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Factors in Predicting Failure with Medical Therapy for BPH.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2005

2.  Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting.

Authors:  Bob Djavan; Yan Kit Fong; Aziz Chaudry; Andreas Reissigl; Theodore Anagnostou; Fariborz Bagheri; Matthias Waldert; Harun Fajkovic; Sibylle Marihart; Mike Harik; Simone Spaller; Mesut Remzi
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

3.  alpha-Blocker Therapy: Current Update.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2005

Review 4.  Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.

Authors:  K L Cooper; J M McKiernan; S A Kaplan
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

5.  Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study.

Authors:  Choal Hee Park; Hyuk Soo Chang; Bong Ryul Oh; Hyung Jee Kim; Chong Koo Sul; Sung Kwang Chung; Se Il Jung
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 6.  The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasia.

Authors:  G M Oades; J D Eaton; R S Kirby
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

Review 7.  Urethral stents in benign prostate hyperplasia.

Authors:  Robert F Donnell
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

8.  Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study.

Authors:  Sung Ryul Shim; Jae Heon Kim; In Ho Chang; In Soo Shin; Sung Dong Hwang; Khae Hwan Kim; Sang Jin Yoon; Yun Seob Song
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.